Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Starts
- Dec 2026
- Expected to end
- 7 Jan 2028
- Type of study
- Observational
- Record updated
- 16 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Adults ≥18 years
- Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids
- Metastatic or unresectable disease
- Cabozantinib initiated between January 2020 and August 2026
Who cannot take part
- Poorly differentiated neuroendocrine carcinoma (NEC), including MiNEN with NEC component
- Missing data for the cabozantinib: date of start or date of stop
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Advanced neuroendocrine carcinoma
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Neuroendocrine tumors are rare tumors with prolonged survival. The management of patients at advanced stage is centered on both locoregional control and systemic therapy. Systemic approaches include somatostatin analogs (SSA) that improve symptom control and slow tumor progression, peptide receptor radionuclide therapy (PRRT), targeted agents (everolimus, sunitinib and cabozantinib) and chemotherapy. All these therapies have demonstrated clinical benefit across multiple randomized and non-randomized studies, yet no high-level evidence defines the optimal sequence in which they should be administered in real-world metastatic settings.
Read full original descriptionShow less
The recent approval of cabozantinib, a multikinase inhibitor targeting VEGFR, MET, and AXL, represents a major advancement in the systemic management of NETs.
The retrospective study "CARE-NET", is a multicenter study which has the aims to describe the real-world use of cabozantinib (between January 2020 and August 2026) in France.
The group in the trial
- Advanced Neuroendocrine Tumors treated by cabozantinib follow in ENDOCAN RENATEN network
Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07939113, who can take part
- Record updated
- 16 November 2026